GB201621635D0 - Crystal structure - Google Patents

Crystal structure

Info

Publication number
GB201621635D0
GB201621635D0 GBGB1621635.0A GB201621635A GB201621635D0 GB 201621635 D0 GB201621635 D0 GB 201621635D0 GB 201621635 A GB201621635 A GB 201621635A GB 201621635 D0 GB201621635 D0 GB 201621635D0
Authority
GB
United Kingdom
Prior art keywords
crystal structure
crystal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1621635.0A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCB Biopharma SRL
Original Assignee
UCB Biopharma SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UCB Biopharma SRL filed Critical UCB Biopharma SRL
Priority to GBGB1621635.0A priority Critical patent/GB201621635D0/en
Publication of GB201621635D0 publication Critical patent/GB201621635D0/en
Priority to US16/470,996 priority patent/US10947304B2/en
Priority to PE2019001251A priority patent/PE20191542A1/es
Priority to TW106144629A priority patent/TWI787223B/zh
Priority to UY0001037528A priority patent/UY37528A/es
Priority to EA201991511A priority patent/EA201991511A1/ru
Priority to NZ754018A priority patent/NZ754018B2/en
Priority to PCT/EP2017/083650 priority patent/WO2018115017A2/en
Priority to MYPI2019003411A priority patent/MY202395A/en
Priority to UAA201906847A priority patent/UA126025C2/uk
Priority to EP17825499.1A priority patent/EP3555129A2/en
Priority to MX2019006630A priority patent/MX2019006630A/es
Priority to BR112019010903-0A priority patent/BR112019010903A2/pt
Priority to KR1020197020545A priority patent/KR102557216B1/ko
Priority to CA3045742A priority patent/CA3045742A1/en
Priority to ARP170103569A priority patent/AR110394A1/es
Priority to MA047669A priority patent/MA47669A/fr
Priority to AU2017384471A priority patent/AU2017384471B2/en
Priority to JP2019533076A priority patent/JP7097364B2/ja
Priority to TNP/2019/000188A priority patent/TN2019000188A1/en
Priority to RU2019122648A priority patent/RU2769285C2/ru
Priority to CN201780079116.0A priority patent/CN110099924B/zh
Priority to CONC2019/0006073A priority patent/CO2019006073A2/es
Priority to PH12019501319A priority patent/PH12019501319A1/en
Priority to ZA2019/03810A priority patent/ZA201903810B/en
Priority to IL267287A priority patent/IL267287A/en
Priority to CL2019001715A priority patent/CL2019001715A1/es
Priority to ECSENADI201951912A priority patent/ECSP19051912A/es
Priority to US17/172,109 priority patent/US11807680B2/en
Priority to US18/502,188 priority patent/US12473355B2/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • General Engineering & Computer Science (AREA)
GBGB1621635.0A 2016-12-19 2016-12-19 Crystal structure Ceased GB201621635D0 (en)

Priority Applications (30)

Application Number Priority Date Filing Date Title
GBGB1621635.0A GB201621635D0 (en) 2016-12-19 2016-12-19 Crystal structure
MA047669A MA47669A (fr) 2016-12-19 2017-12-19 Structure cristalline de gremlin-1 et anticorps inhibiteur
CA3045742A CA3045742A1 (en) 2016-12-19 2017-12-19 Gremlin-1 crystal structure and inhibitory antibody
ARP170103569A AR110394A1 (es) 2016-12-19 2017-12-19 Estructura del cristal de gremlin-1 y anticuerpo inhibidor
TW106144629A TWI787223B (zh) 2016-12-19 2017-12-19 Gremlin-1結晶結構及抑制抗體
UY0001037528A UY37528A (es) 2016-12-19 2017-12-19 Estructura del cristal de gremlin-1 y anticuerpo inhibidor
EA201991511A EA201991511A1 (ru) 2016-12-19 2017-12-19 Кристаллическая структура гремлин-1 и ингибирующее антитело
NZ754018A NZ754018B2 (en) 2017-12-19 Gremlin-1 crystal structure and inhibitory antibody
PCT/EP2017/083650 WO2018115017A2 (en) 2016-12-19 2017-12-19 Gremlin-1 crystal structure and inhibitory antibody
MYPI2019003411A MY202395A (en) 2016-12-19 2017-12-19 Gremlin-1 crystal structure and inhibitory antibody
UAA201906847A UA126025C2 (uk) 2016-12-19 2017-12-19 Кристалічна структура гремліну-1 та інгібіторне антитіло
EP17825499.1A EP3555129A2 (en) 2016-12-19 2017-12-19 Gremlin-1 crystal structure and inhibitory antibody
MX2019006630A MX2019006630A (es) 2016-12-19 2017-12-19 Estructura cristalina de gremlina 1 y anticuerpo inhibidor.
BR112019010903-0A BR112019010903A2 (pt) 2016-12-19 2017-12-19 estrutura de cristal de gremlin-1 e anticorpo inibidor
KR1020197020545A KR102557216B1 (ko) 2016-12-19 2017-12-19 그렘린-1 결정 구조 및 억제 항체
US16/470,996 US10947304B2 (en) 2016-12-19 2017-12-19 Gremlin-1 antibody
AU2017384471A AU2017384471B2 (en) 2016-12-19 2017-12-19 Gremlin-1 crystal structure and inhibitory antibody
CN201780079116.0A CN110099924B (zh) 2016-12-19 2017-12-19 Gremlin-1晶体结构和抑制性抗体
PE2019001251A PE20191542A1 (es) 2016-12-19 2017-12-19 Estructura cristalina de gremlina 1 y anticuerpo inhibidor
JP2019533076A JP7097364B2 (ja) 2016-12-19 2017-12-19 グレムリン－１の結晶構造及び阻害抗体
TNP/2019/000188A TN2019000188A1 (en) 2016-12-19 2017-12-19 Gremlin-1 crystal structure and inhibitory antibody
RU2019122648A RU2769285C2 (ru) 2016-12-19 2017-12-19 Кристаллическая структура гремлин-1 и ингибирующее антитело
PH12019501319A PH12019501319A1 (en) 2016-12-19 2019-06-11 Gremlin-1 crystal structure and inhibitory antibody
CONC2019/0006073A CO2019006073A2 (es) 2016-12-19 2019-06-11 Estructura cristalina de gremlina 1 y anticuerpo inhibidor
ZA2019/03810A ZA201903810B (en) 2016-12-19 2019-06-12 Gremlin-1 crystal structure and inhibitory antibody
IL267287A IL267287A (en) 2016-12-19 2019-06-12 Gremlin-1 crystal structure and inhibitory antibody
CL2019001715A CL2019001715A1 (es) 2016-12-19 2019-06-19 Estructura cristalina de gremlina 1 y anticuerpo inhibidor.
ECSENADI201951912A ECSP19051912A (es) 2016-12-19 2019-07-19 Estructura cristalina de gremlina 1 y anticuerpo inhibidor
US17/172,109 US11807680B2 (en) 2016-12-19 2021-02-10 Gremlin-1 crystal structure and inhibitory antibody
US18/502,188 US12473355B2 (en) 2016-12-19 2023-11-06 Gremlin-1 crystal structure and inhibitory antibody

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1621635.0A GB201621635D0 (en) 2016-12-19 2016-12-19 Crystal structure

Publications (1)

Publication Number Publication Date
GB201621635D0 true GB201621635D0 (en) 2017-02-01

Family

ID=58284547

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1621635.0A Ceased GB201621635D0 (en) 2016-12-19 2016-12-19 Crystal structure

Country Status (27)

Country Link
US (3) US10947304B2 (enExample)
EP (1) EP3555129A2 (enExample)
JP (1) JP7097364B2 (enExample)
KR (1) KR102557216B1 (enExample)
CN (1) CN110099924B (enExample)
AR (1) AR110394A1 (enExample)
AU (1) AU2017384471B2 (enExample)
BR (1) BR112019010903A2 (enExample)
CA (1) CA3045742A1 (enExample)
CL (1) CL2019001715A1 (enExample)
CO (1) CO2019006073A2 (enExample)
EA (1) EA201991511A1 (enExample)
EC (1) ECSP19051912A (enExample)
GB (1) GB201621635D0 (enExample)
IL (1) IL267287A (enExample)
MA (1) MA47669A (enExample)
MX (1) MX2019006630A (enExample)
MY (1) MY202395A (enExample)
PE (1) PE20191542A1 (enExample)
PH (1) PH12019501319A1 (enExample)
RU (1) RU2769285C2 (enExample)
TN (1) TN2019000188A1 (enExample)
TW (1) TWI787223B (enExample)
UA (1) UA126025C2 (enExample)
UY (1) UY37528A (enExample)
WO (1) WO2018115017A2 (enExample)
ZA (1) ZA201903810B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201621635D0 (en) 2016-12-19 2017-02-01 Ucb Biopharma Sprl Crystal structure
GB201802486D0 (en) * 2018-02-15 2018-04-04 Ucb Biopharma Sprl Methods
EP3806898B1 (en) * 2018-06-18 2025-10-08 UCB Biopharma SRL Gremlin-1 antagonist for use in the treatment of cancer
CN116848135A (zh) * 2021-01-18 2023-10-03 苏州创胜医药集团有限公司 新颖的抗gremlin1抗体
AU2022233762A1 (en) * 2021-03-11 2023-10-05 Shanghai Jiao Tong University Method of treating diseases using gremlin1 antagonists
GB202205203D0 (en) 2022-04-08 2022-05-25 UCB Biopharma SRL Combination with inhibitor
GB202205200D0 (en) 2022-04-08 2022-05-25 Ucb Biopharma Sprl Combination with chemotherapy
CA3243581A1 (en) * 2022-04-20 2023-10-26 Kantonsspital St. Gallen ANTIBODIES OR ANTIGEN-BINDING FRAGMENTS THAT BIND PANSPECIFICALLY TO GREMLIN-1 AND GREMLIN-2 AND RELATED USES
WO2024258870A2 (en) 2023-06-12 2024-12-19 Amgen Inc. Lymphotoxin beta receptor agonist binding proteins

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
DK336987D0 (da) 1987-07-01 1987-07-01 Novo Industri As Immobiliseringsmetode
GB8719042D0 (en) 1987-08-12 1987-09-16 Parker D Conjugate compounds
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
DE768377T1 (de) 1988-09-02 1998-01-02 Dyax Corp Herstellung und Auswahl von Rekombinantproteinen mit verschiedenen Bindestellen
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
GB8907617D0 (en) 1989-04-05 1989-05-17 Celltech Ltd Drug delivery system
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
WO1991010737A1 (en) 1990-01-11 1991-07-25 Molecular Affinities Corporation Production of antibodies using gene libraries
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
ATE139258T1 (de) 1990-01-12 1996-06-15 Cell Genesys Inc Erzeugung xenogener antikörper
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
CA2090126C (en) 1990-08-02 2002-10-22 John W. Schrader Methods for the production of proteins with a desired function
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
CA2095633C (en) 1990-12-03 2003-02-04 Lisa J. Garrard Enrichment method for variant proteins with altered binding properties
WO1992018619A1 (en) 1991-04-10 1992-10-29 The Scripps Research Institute Heterodimeric receptor libraries using phagemids
GB9112536D0 (en) 1991-06-11 1991-07-31 Celltech Ltd Chemical compounds
GB9113120D0 (en) 1991-06-18 1991-08-07 Kodak Ltd Photographic processing apparatus
GB9120467D0 (en) 1991-09-26 1991-11-06 Celltech Ltd Anti-hmfg antibodies and process for their production
ES2341666T3 (es) 1991-12-02 2010-06-24 Medimmune Limited Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
EP0733070A1 (en) 1993-12-08 1996-09-25 Genzyme Corporation Process for generating specific antibodies
EP1231268B1 (en) 1994-01-31 2005-07-27 Trustees Of Boston University Polyclonal antibody libraries
FR2716640B1 (fr) 1994-02-28 1996-05-03 Procedes Machines Speciales Dispositif de centrage et de blocage d'une pièce en vue de son rodage à l'aide d'un rodoir à expansion.
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
JP2978435B2 (ja) 1996-01-24 1999-11-15 チッソ株式会社 アクリロキシプロピルシランの製造方法
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
EP1357828A2 (en) 2001-01-12 2003-11-05 University of Medicine and Dentistry of New Jersey Bone morphogenetic protein-2 in the treatment and diagnosis of cancer
US6908963B2 (en) 2001-10-09 2005-06-21 Nektar Therapeutics Al, Corporation Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
PT1570267E (pt) 2002-12-03 2012-01-03 Ucb Pharma Sa Ensaio para a identificação de células produtoras de anticorpos
GB0312481D0 (en) 2003-05-30 2003-07-09 Celltech R&D Ltd Antibodies
GB0315450D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
US7989594B2 (en) 2003-07-01 2011-08-02 Celltech R & D Limited Modified antibody fab fragments
EP2824190A1 (en) 2003-09-09 2015-01-14 Integrigen, Inc. Methods and compositions for generation of germline human antibody genes
EP1571159A1 (en) 2004-03-04 2005-09-07 Bayerische Julius-Maximilians-Universität Würzburg Mutein of a bone morphogenetic protein and use thereof
GB0411186D0 (en) 2004-05-19 2004-06-23 Celltech R&D Ltd Biological products
GB0412181D0 (en) 2004-06-01 2004-06-30 Celltech R&D Ltd Biological products
US20090203041A1 (en) 2006-04-21 2009-08-13 Wei Shi Bmp4 inhibitors
GB0619291D0 (en) 2006-09-29 2006-11-08 Ucb Sa Altered antibodies
US8383349B2 (en) 2007-03-16 2013-02-26 The Board Of Trustees Of The Leland Stanford Junior University Bone morphogenetic protein antagonist and uses thereof
CA2700714C (en) 2007-09-26 2018-09-11 Ucb Pharma S.A. Dual specificity antibody fusions
EP2826790B1 (en) * 2012-03-15 2019-02-13 SNU R&DB Foundation Anti-gremlin-1 antibody
EP2970448B1 (en) * 2013-03-14 2021-11-03 Regeneron Pharmaceuticals, Inc. Human antibodies to grem 1
GB201621635D0 (en) 2016-12-19 2017-02-01 Ucb Biopharma Sprl Crystal structure
GB201802486D0 (en) 2018-02-15 2018-04-04 Ucb Biopharma Sprl Methods
EP3806898B1 (en) 2018-06-18 2025-10-08 UCB Biopharma SRL Gremlin-1 antagonist for use in the treatment of cancer

Also Published As

Publication number Publication date
TW201837052A (zh) 2018-10-16
JP7097364B2 (ja) 2022-07-07
ZA201903810B (en) 2020-12-23
KR20190093658A (ko) 2019-08-09
US11807680B2 (en) 2023-11-07
ECSP19051912A (es) 2019-07-31
US12473355B2 (en) 2025-11-18
CL2019001715A1 (es) 2019-11-29
RU2769285C2 (ru) 2022-03-30
UY37528A (es) 2018-07-31
US10947304B2 (en) 2021-03-16
CN110099924B (zh) 2023-11-10
CO2019006073A2 (es) 2019-06-19
US20190330323A1 (en) 2019-10-31
AU2017384471A1 (en) 2019-06-13
RU2019122648A3 (enExample) 2021-07-02
US20210163586A1 (en) 2021-06-03
AR110394A1 (es) 2019-03-27
MY202395A (en) 2024-04-25
JP2020511946A (ja) 2020-04-23
AU2017384471B2 (en) 2024-08-22
MX2019006630A (es) 2019-08-21
US20240076365A1 (en) 2024-03-07
IL267287A (en) 2019-08-29
PE20191542A1 (es) 2019-10-23
MA47669A (fr) 2020-01-08
EA201991511A1 (ru) 2019-11-29
NZ754018A (en) 2024-07-26
PH12019501319A1 (en) 2020-03-02
EP3555129A2 (en) 2019-10-23
TWI787223B (zh) 2022-12-21
KR102557216B1 (ko) 2023-07-18
RU2019122648A (ru) 2021-01-19
WO2018115017A2 (en) 2018-06-28
BR112019010903A2 (pt) 2019-10-01
CN110099924A (zh) 2019-08-06
CA3045742A1 (en) 2018-06-28
TN2019000188A1 (en) 2020-10-05
UA126025C2 (uk) 2022-08-03
WO2018115017A3 (en) 2019-02-07

Similar Documents

Publication Publication Date Title
AU367507S (en) Display structure
AU364424S (en) Watchcase
GB201501409D0 (en) Display
AU364423S (en) Watchcase
GB201412161D0 (en) Structure
GB2528078B (en) Structure
AU359665S (en) Watchcase
GB201511677D0 (en) Crystal defects
GB201621635D0 (en) Crystal structure
GB2522522B (en) Structure
DK3177838T3 (en) Fluid-redirecting structure
IL262674A (en) crystals
GB201411161D0 (en) Support structures
GB201511225D0 (en) Novel structure
TWI562107B (en) Display
IL273430A (en) crystal
GB201610183D0 (en) Structure
PL3257657T3 (pl) Struktura zapobiegająca wyciekaniu
GB2547832B (en) Backlight module structures
EP3151850A4 (en) Crystal forms
ZA201807587B (en) Polytunnel structure
GB201610190D0 (en) Structure
TWM533755U (en) Glasses-frame combination structure
SG10201508927SA (en) Protein crystal
GB201519083D0 (en) Crystal structure

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)